COMy 2021 | Evolving induction and maintenance strategies in myeloma
Saad Usmani, MD, University of North Carolina School of Medicine, Chapel Hill, NC, talks on the evolving optimal approaches for induction and maintenance therapy for patients with multiple myeloma. Strong data from large randomized clinical trials are demonstrating the benefits of monoclonal antibody-based combinations in the front-line setting. Dr Usmani notes that more mature data sets are needed, but hopes we are beginning to move into an era where antibodies can be used as initial induction therapy. For maintenance therapy, proteasome inhibitors and immunomodulatory drugs are under investigation. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Research funding: Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Consulting fees: Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, Takeda
Speaking fees: Celgene, Janssen, Sanofi, Takeda
